Melatonin-MT1 Signaling Axis Ameliorates the Phenotypes of Primary Sclerosing Cholangitis

Abstract

Background: Primary Sclerosing Cholangitis (PSC) is characterized by hepatic fibrosis and portal inflammation. Melatonin is synthesized by arylalkylamine N-acetyltransferase (AANAT) in cholangiocytes. We found that: (i) the MT1 receptor is primarily expressed in cholangiocytes; (ii) melatonin reduces biliary proliferation via MT1 receptor signaling; and (iii) melatonin treatment for 1 wk decreases ductular reaction (DR) and liver fibrosis in cholestatic rats by downregulation of MT1 and clock genes. Melatonin administration to male Mdr2-/- mice (PSC model) reduces angiogenesis and portal inflammation via decreased miR-200b. Downregulation of maspin triggers angiogenesis during tumorigenesis by interaction with glutathione S-transferase (GST). We aimed to evaluate the effects of long-term melatonin treatment and MT1 signaling on PSC phenotypes in Mdr2-/- mice. Methods: Male FVB/NJ and Mdr2-/- mice had access ad libitum to drinking water with/without melatonin for 3 months. Immortilized-SV40-cholangiocytes isolated from human liver samples (control and PSC) were treated with melatonin (10-3 mol/L) for 24 hr. Male C3H-Hej (WT for MT1-/-), FVB/NJ (WT for Mdr2-/-), MT1-/-, Mdr2-/- mice and MT1-/-/Mdr2-/- mice were euthanized at 12 wk. We analyzed liver damage, PSC phenotypes, angiogenesis and AANAT, melatonin receptors and clock genes by immunohistochemistry, immunofluorescence, ELISA and western blots in liver samples and isolated cholangiocytes. Melatonin signaling was evaluated in human control and PSC samples. Results: Long-term melatonin treatment and inhibition of MT1 receptor ameliorates cholestatic liver phenotypes in Mdr2-/-mice by decreasing the immunoreactivity of melatonin enzymes and clock genes. GST activity and maspin expression decreased in Mdr2-/- mice and human PSC samples compared to controls; the phenotypes were reversed by melatonin. Conclusion: Chronic melatonin treatment improves liver histology and restores biliary circadian rhythm by interaction with MT1. Suppression of MT1 ameliorates biliary/liver phenotypes through changes in clock genes and melatonin enzymes. Restoration of the circadian rhythm by modulation of melatonin/MT1 signaling may be key for PSC management.